Commercialising innovative new medicines
As pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination of evidence generation and communication
Working with all stakeholders to generate evidence that communicates value, from early phase development to launch and reimbursement, is essential in therapy areas including oncology.
These are challenging times for the pharmaceutical industry as it navigates an oncology landscape offering an increasing array of new ways to target and treat cancer.
The rise of ever-more personalised treatments for different tumour types, a greater understanding of the mutations that cause cancers and the increasingly central role of combination therapies are just some of the factors that make this a particularly complicated and competitive space.
• Read the full article in pharmaphorum’s Deep Dive digital magazine